Recently, our group and others reported a therapeutic effect of GSK3β inhibition against osteosarcoma [151,152,153,154], rhabdomyosarcoma [155,156], synovial sarcoma and fibrosarcoma [157]. Here, GSK3B is linked to osteosarcoma.